Virtual Library
Start Your Search
- Virtual Library Home
- IASLC Library
- Explore Event
-
WCLC 2016
17th World Conference on Lung Cancer
Access to all presentations that occur during the 17th World Conference on Lung Cancer in Vienna, Austria
Presentation Date(s):- Dec 4 - 7, 2016
- Total Presentations: 2466
To review abstracts of the presentations below, narrow down your search by using the Filter options below, and then select the session listing of your choice. Click the "+" for a presentation to expand & view the corresponding Abstract details.
Presentations will be available 24 hours after their live presentation time
-
+
ISS04 - Industry Supported Symposium: Treatment Selection Strategies in Advanced NSCLC - A Symphony of Views - Eli Lilly and Company
- Type: Industry Supported Symposium
- Track:
- Presentations: 6
- Moderators:G.V. Scagliotti
- Coordinates: 12/04/2016, 17:15 - 18:45, Hall C1
-
+
ISS04.01 - Welcome & Introduction
17:15 - 17:20 | Author(s): G.V. Scagliotti
- Abstract
No abstract available for this presentation
-
+
ISS04.02 - Orchestral Manoeuvres of the Immuno Checkpoints: Targeted or Untargeted Agents?
17:20 - 17:45 | Author(s): J.G. Aerts
- Abstract
No abstract available for this presentation
-
+
ISS04.03 - Variation on a Theme: Angiogenesis Inhibition Across Treatment Lines
17:45 - 18:05 | Author(s): M. Pérol
- Abstract
No abstract available for this presentation
-
+
ISS04.04 - Keys to Biomarker Driven Choices in 2nd Line
18:05 - 18:25 | Author(s): L. Paz-Arez
- Abstract
No abstract available for this presentation
-
+
ISS04.05 - Is the Score Yet Written?
18:25 - 18:30 | Author(s): G.V. Scagliotti
- Abstract
No abstract available for this presentation
-
+
ISS04.06 - Discussion: The Unfinished Symphony
18:30 - 18:45 | Author(s): T. Mok
- Abstract
No abstract available for this presentation
-
+
SC12 - Anticancer Drug Development in the 21st Century
- Type: Science Session
- Track: Chemotherapy/Targeted Therapy/Immunotherapy
- Presentations: 5
- Moderators:L. Einhorn
- Coordinates: 12/05/2016, 16:00 - 17:30, Hall C2
-
+
SC12.01 - Establishment of EGFR Tyrosine Kinase Inhibitors: History and Lessons Learned for Future Drug Development
16:00 - 16:25 | Author(s): T. Mok
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
PL03 - Presidential Symposium
- Type: Plenary
- Track:
- Presentations: 10
- Moderators:D.P. Carbone
- Coordinates: 12/06/2016, 08:35 - 10:25, Hall D (Plenary Hall)
-
+
PL03.03 - Randomised Phase III Study of Osimertinib vs Platinum-Pemetrexed for EGFR T790M-Positive Advanced NSCLC (AURA3) (Abstract under Embargo until December 6, 7:00 CET)
09:05 - 09:15 | Author(s): V. Papadimitrakopoulou
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
PR03 - Press Conference: Accurate Diagnosis
- Type: Press Conference
- Track:
- Presentations: 4
- Moderators:T. Mok
- Coordinates: 12/06/2016, 10:30 - 11:45, Schubert 1
-
+
PR03.01 - Lung Cancer Staging – Changing the Clinical Practice
10:30 - 10:30 | Author(s): R. Rami-Porta
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
PR03.02 - Randomised Phase III Study of Osimertinib vs Platinum-Pemetrexed for EGFR T790M-Positive Advanced NSCLC (AURA3)
10:30 - 10:30 | Author(s): V. Papadimitrakopoulou
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
PR03.03 - BRAIN: A Phase Ⅲ Trial Comparing WBI and Chemotherapy with Icotinib in NSCLC with Brain Metastases Harboring EGFR Mutations (CTONG 1201)
10:30 - 10:30 | Author(s): Y.-. Wu
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
PR03.04 - First-line Ceritinib Versus Chemotherapy in Patients With ALK-rearranged (ALK+) NSCLC: A Randomized, Phase 3 Study (ASCEND-4)
10:30 - 10:30 | Author(s): G. De Castro Jr
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
MA08 - Treatment Monitoring in Advanced NSCLC
- Type: Mini Oral Session
- Track: Advanced NSCLC
- Presentations: 12
- Moderators:R. Perez-Soler
- Coordinates: 12/06/2016, 11:00 - 12:30, Lehar 3-4
-
+
MA08.03 - Osimertinib vs Platinum-Pemetrexed for T790M-Mutation Positive Advanced NSCLC (AURA3): Plasma ctDNA Analysis
11:12 - 11:18 | Author(s): Y.-. Wu
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
P2.06 - Poster Session with Presenters Present
- Type: Poster Presenters Present
- Track: Scientific Co-Operation/Research Groups (Clinical Trials in Progress should be submitted in this category)
- Presentations: 47
- Coordinates: 12/06/2016, 14:30 - 15:45, Hall B (Poster Area)
-
+
P2.06-022 - First-Line Durvalumab plus Tremelimumab vs Platinum-Based Chemotherapy for Advanced/Metastatic NSCLC: Phase 3 NEPTUNE Study
14:30 - 14:30 | Author(s): T. Mok
- Abstract
Loading...
-
+
MA16 - Novel Strategies in Targeted Therapy
- Type: Mini Oral Session
- Track: Chemotherapy/Targeted Therapy/Immunotherapy
- Presentations: 12
- Moderators:G. Purkalne
- Coordinates: 12/07/2016, 14:20 - 15:50, Strauss 2
-
+
MA16.03 - Global RET Registry (GLORY): Activity of RET-Directed Targeted Therapies in RET-Rearranged Lung Cancers
14:26 - 14:32 | Author(s): O. Gautschi
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
OA23 - EGFR Targeted Therapies in Advanced NSCLC
- Type: Oral Session
- Track: Advanced NSCLC
- Presentations: 8
- Moderators:O.T. Brustugun
- Coordinates: 12/07/2016, 14:20 - 15:50, Stolz 2
-
+
OA23.05 - First-Line Afatinib versus Gefitinib in EGFRm+ Advanced NSCLC: Updated Overall Survival Analysis of LUX-Lung 7
15:05 - 15:15 | Author(s): K. Park
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
P3.02b - Poster Session with Presenters Present
- Type: Poster Presenters Present
- Track: Advanced NSCLC
- Presentations: 126
- Coordinates: 12/07/2016, 14:30 - 15:45, Hall B (Poster Area)
-
+
P3.02b-044 - Afatinib versus Gefitinib as First-Line Treatment for EGFR Mutation-Positive NSCLC Patients Aged ≥75 Years: Subgroup Analysis of LUX-Lung 7
14:30 - 14:30 | Author(s): K. Park
- Abstract
Loading...
-
+
P3.02c - Poster Session with Presenters Present
- Type: Poster Presenters Present
- Track: Advanced NSCLC
- Presentations: 103
- Coordinates: 12/07/2016, 14:30 - 15:45, Hall B (Poster Area)
-
+
P3.02c-038 - First-Line Atezolizumab plus Chemotherapy in Chemotherapy-Naïve Patients with Advanced NSCLC: A Phase III Clinical Program
14:30 - 14:30 | Author(s): F. Cappuzzo
- Abstract
Loading... -
+
P3.02c-041 - IMpower133: A Phase I/III Study of 1L Atezolizumab with Carboplatin and Etoposide in Patients with Extensive-Stage SCLC
14:30 - 14:30 | Author(s): S.V. Liu
- Abstract
Loading...
